# Genesis RMN / GenesisX: robot model

Canonical ID: `eca99ad0-d6db-401f-9575-6e22a77bfc14`

- **Slug:** stereotaxis-genesis
- **Form factor:** surgical
- **Maturity stage:** commercial
- **Lifecycle:** active
- **Deployments registered:** 0

## Specs

- **notes:** [object Object],[object Object],[object Object],[object Object]
- **products:** Genesis RMN (current-gen robotic magnetic navigation, FDA-cleared, succeeded legacy Niobe); GenesisX (next-gen small-footprint RMN, CE Aug 2024, FDA 510(k) Nov 10 2025); MAGiC magnetic ablation catheter (FDA approval Jan 6 2026); plus an imaging system. Niche: electrophysiology / cardiac ablation.
- **formFactor:** surgical (robotic magnetic navigation: robotically steers magnetic-tipped catheters inside the heart via external magnets)

## Deployments

_No deployments registered for this model._

## Supply chain

_No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this model's suppliers._

_Suppliers appear when verified with at least two strong sources. Sources are append-only; corrections add new sources rather than rewrite history._

## Common questions

### What is Genesis RMN / GenesisX?

Stereotaxis (NYSE American: STXS; headquartered in St. Louis, Missouri) pioneered Robotic Magnetic Navigation, a distinct surgical-robot modality in which two large external magnets robotically steer a magnetic-tipped catheter inside the heart for catheter-based electrophysiology and cardiac ablation. It is genuinely a robot, with computer-controlled physical actuation of an in-body instrument, but an unusual one whose manipulator is the magnetic field acting on a soft catheter rather than a rigid arm, placing it in a distinct endovascular sub-category rather than the soft-tissue laparoscopic mainstream. Its current-generation Genesis RMN system succeeded the legacy Niobe, the next-generation small-footprint GenesisX received its European CE mark in August 2024 and US FDA 510(k) clearance on November 10, 2025, and the MAGiC magnetic ablation catheter that the system steers received FDA approval on January 6, 2026, with the first US procedure performed at OHSU. The registry records it at commercial maturity, with more than 100 RMN systems installed across about 31 countries, public-company revenue, and GenesisX in early limited launch, and notes that the company signed an agreement to acquire the endovascular-robotics firm Robocath in early 2026. A correction to the dispatch framing: no Stereotaxis product named Mavericks exists in any primary source, and the real third leg of the portfolio is the MAGiC ablation catheter, so Mavericks is not recorded. The figure of more than 140,000 cumulative patients is a company marketing figure, and exact current GenesisX install counts beyond a first installation and limited launch are not verified.

### Who makes Genesis RMN / GenesisX?

Genesis RMN / GenesisX is made by Stereotaxis, based in St. Louis, Missouri, USA, founded in 1990.

### Where is Genesis RMN / GenesisX deployed?

No verified deployments of Genesis RMN / GenesisX are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.

### What is Genesis RMN / GenesisX's maturity stage?

Genesis RMN / GenesisX is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.


## Sources (4)

1. https://www.globenewswire.com/news-release/2025/11/10/stereotaxis-genesisx-fda-clearance
2. https://www.globenewswire.com/news-release/2026/01/06/stereotaxis-magic-catheter-fda
3. https://www.globenewswire.com/news-release/2026/05/12/stereotaxis-q1-2026-results
4. https://en.wikipedia.org/wiki/Stereotaxis

_API: GET /v1/models/eca99ad0-d6db-401f-9575-6e22a77bfc14 · canonical URL: /models/stereotaxis-genesis_